Pre-made Odulimomab benchmark antibody (Fab Fusion, anti-ITGAL therapeutic antibody, Anti-CD11A/LFA-1/LFA1A Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Odulimomab benchmark antibody (Fab Fusion, anti-ITGAL therapeutic antibody, Anti-CD11A/LFA-1/LFA1A Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Odulimomab is an investigational drug for the prevention of transplant rejection[1][2] and for the treatment of various immunological diseases.[3][4]
| Products Name (INN Index) | Pre-Made Odulimomab Biosimilar, Fab Fusion, Anti-Itgal Antibody: Anti-CD11A/LFA-1/LFA1A therapeutic antibody |
|---|---|
| INN Name | odulimomab |
| Target | ITGAL |
| Format | Fab Fusion |
| Derivation | Mus musculus |
| Species Reactivity | Human |
| CH1 Isotype | F(ab')2 – G1 – nd |
| VD LC | F(ab')2 – G1 – nd |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Pasteur M (Lyon France) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ITGAL |
| Package |
